Health Technology

Nichi-Iko Pharmaceutical Co., Ltd.

In the news

Japan greenlights dexamethasone as second coronavirus treatment Jul 22, 2020
Coronavirus: Week of June 14 to June 20, US rejects extra flights for Chinese airlines Jun 20, 2020
Japan's generic drugmakers have a China dependency problem Nov 5, 2019
China extends drug patents to 25 years May 16, 2018
Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018

See more articles on Nichi-Iko Pharmaceutical Co., Ltd.

Business Summary

Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	179,060M	1,593.44M
Gross Profit	3,975M	35.37M
Operating income	-28,152M	-250.52M
Income before tax	-107,964M	-960.76M
Net income	-104,875M	-933.27M
EBITDA	-15,499M	-137.92M
Diluted EPS	-1,552.73	-13.81
Dividends Per Share	--	--
Total Assets	260,672M	2,147.65M
Total liabilities	246,753M	2,032.98M
Total equity	13,536M	111.52M
Operating cash flow	-24,248M	-215.78M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	164,717M	166,592M	190,076M	188,218M	179,060M
Gross Profit	40,803M	33,158M	37,320M	21,245M	3,975M
Operating income	13,200M	7,221M	7,572M	-9,867M	-28,152M
Income before tax	9,067M	8,903M	7,396M	636M	-107,964M
Net income	8,069M	6,864M	5,133M	-4,180M	-104,875M
EBITDA	22,179M	16,987M	19,443M	3,350M	-15,499M
Diluted EPS	142.92	114.03	80.12	-65.27	-1,552.73
Dividends Per Share	30	30	30	25	--
Total Assets	278,364M	306,838M	336,819M	363,572M	260,672M
Total liabilities	190,819M	190,511M	219,644M	251,134M	246,753M
Total equity	87,542M	116,323M	115,827M	111,167M	13,536M
Operating cash flow	18,925M	23,811M	18,450M	5,006M	-24,248M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	1,486.18M	1,502.25M	1,748.21M	1,774.68M	1,593.44M
Gross Profit	368.15M	299.00M	343.24M	200.31M	35.37M
Operating income	119.09M	65.11M	69.64M	-93.03M	-250.52M
Income before tax	81.80M	80.28M	68.02M	5.99M	-960.76M
Net income	72.80M	61.89M	47.21M	-39.41M	-933.27M
EBITDA	200.11M	153.18M	178.82M	31.58M	-137.92M
Diluted EPS	1.28	1.02	0.73	-0.61	-13.81
Dividends Per Share	0.27	0.27	0.27	0.23	--
Total Assets	2,617.43M	2,772.17M	3,119.99M	3,290.24M	2,147.65M
Total liabilities	1,794.25M	1,721.19M	2,034.58M	2,272.70M	2,032.98M
Total equity	823.14M	1,050.93M	1,072.91M	1,006.03M	111.52M
Operating cash flow	170.75M	214.71M	169.69M	47.20M	-215.78M

Valuation Measures

Mar 2022
PER	--
ROA	-33.60%
ROE	-168.19%
Operating margin	-15.72%
Profit margin	-58.56%

Key executives

President & Representative Director: Yuichi Tamura
Finance Manager: Naoyuki Okada
Head-Compliance Management & Guidance: Yasutomo Sai
Director, VP, Head-CSR, ESG & Business Creation: Kenji Akane
Executive Officer & Personnel Manager: Keiichi Arakawa

Shareholders

TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (11.8%)
Medipal Holdings Corp. (9.7%)
Hokuhoku Financial Group, Inc. (3.9%)
Nomura Asset Management Co., Ltd. (2.6%)
Dimensional Fund Advisors LP (2.2%)
The Vanguard Group, Inc. (1.9%)
Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
Nichi-Iko Pharmaceutical Co., Ltd. (1.3%)
Nikko Asset Management Co., Ltd. (1.2%)
Daiwa Asset Management Co. Ltd. (1.2%)

Contact Details

Website:http://www.nichiiko.co.jp
Phone: +81.76.432.2121

Related Companies

Nichi Iko Business Association
Nichi Iko Pharmaceutical Co. /Toyama Daini Kojo/
Nichi-Iko Gifu Plant Co., Ltd.
Nichi-Iko Pharma Tech Co., Ltd.
Elmed Co., Ltd.
Nichi Iko Pharmaceutical Trust
SterRx LLC
Nichi-Iko Pharmaceutical Employee Incentive Plan
Nichiiko Pharma KK
Nichiiko Osaka KK
Yakuhan Pharmaceutical Co., Ltd.
Sagent Pharmaceuticals, Inc.
Kobayashi Pharmaceutical Industries Co. Ltd.
Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
Oriental Pharmaceutical Co., Ltd.
Teikoku Medix Co., Ltd.
Japan Galen, Inc.
Maruko Pharmaceutical Co. Ltd.
Nichiiko Pharmaceutical Employee Stock Pwnership Plan

Competitors

Dr. Reddy's Laboratories Ltd.
Cumberland Pharmaceuticals Inc.
Amphastar Pharmaceuticals, Inc.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A

Last Updated on 24 Jun, 2022